Ref: NEPHROPLUS/SE/96

November 3, 2026

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai – 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Sub: Press Release on Q2FY27 Financial Results
Ref: Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI Listing Regulations, please find enclosed Press Release on the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.

Yours faithfully,
For Nephrocare Health Services Limited
(Formerly Nephrocare Health Services Private Limited)

Kathri Kishore
Digitally signed by Kathri Kishore
Date: 2026.11.03 18:06:21 +05'30'

Kishore Kathri
Company Secretary and Head Legal
Membership No.: F9895

Encl: a/a

Nephrocare Health Services Limited

Hyderabad, 3rd November 2026 – Nephrocare Health Services Limited, Asia's largest dialysis network under the brand "NephroPlus" announced its Financial Results for second quarter and half year ended 30th September 2026.

Consolidated Performance: Q2 & H1FY27						
Particulars (INR Cr)	**Q2FY27**	**Q2FY26**	**YoY**	**H1FY27**	**H1FY26**	**YoY**
Revenue	**303.4**	**245.7**	**23.5%**	**585.2**	**473.5**	**23.6%**
Adj. EBITDA*	**68.9**	**66.7**	**3.3%**	**134.4**	**116.5**	**15.3%**
*Adj. EBITDA Margin**	**22.7%**	**27.1%**	**(443) bps**	**23.0%**	**24.6%**	**(165) bps**
Adj. PAT#	**39.3**	**30.5**	**28.7%**	**76.1**	**56.5**	**34.7%**
Adj. PAT Margin#	**12.9%**	**12.4%**	**+52 bps**	**13.0%**	**11.9%**	**+107 bps**

**EBITDA adjusted for ESOP expenses of Rs. 1.8 crores in Q2FY27, Rs. 2.8 crores in Q2FY26, Rs. 3.1 crores in H1 FY27 and Rs. 5.0 crores in H1 FY26;*

#PAT adjusted for share of loss from JV of Rs. 3.9 crores and ESOP expenses of Rs. 1.8 crores in Q2 FY27, ESOP expenses of Rs. 2.8 crores and Impact on Finance costs on account of CCPS conversion of Rs. 37.2 crores in Q2 FY26, share of loss from JV of Rs. 7.5 crores and ESOP expenses of Rs. 3.1 crores in H1 FY27, ESOP expenses of Rs. 5.0 crores and Impact on Finance costs on account of CCPS conversion of Rs. 37.2 crores in H1 FY26.

Operational Highlights: Q2 & H1FY27						
Particulars	**Q2FY27**	**Q2FY26**	**YoY**	**H1FY27**	**H1FY26**	**YoY**
Treatments	10,70,105	9,55,685	12.0%	21,01,189	18,65,545	12.6%
RPT (Revenue Per Treatment)	2,835	2,571	10.3%	2,785	2,538	9.7%
Guests	38,814	35,425	9.6%	38,814	35,425	9.6%

Key Q2 & H1 FY2027 Performance Highlights

- **H1FY27 revenue of ₹ 585.2 crore, an increase of 23.6% YoY; driven by –**
  - Treatments up 12.6% YoY to 21.01 lakh (H1FY26: 18.66 lakh) and guests up 9.6% YoY to 38,814, alongside a 9.7% YoY increase in revenue per treatment to ₹2,785 (H1FY26: ₹2,538)
- **H1FY27 Adjusted EBITDA* of ₹ 134.4 crore, an increase of 15.3% YoY**
  - Healthy Adjusted EBITDA margin of 23.0%, while investing in clinical talent and network expansion; Q2FY27 Adjusted EBITDA up 5.8% QoQ to ₹68.9 crore
  - Adjusted PAT grew 34.7% YoY to ₹76.1 crore (H1FY26: ₹56.5 crore); margin up 107 bps to 13.0%
- Network expanded to 570 clinics across 6 countries with entry into Kazakhstan; international business now ~47% of revenue

***EBITDA adjusted for ESOP expenses**

Commenting on the Q2 & H1FY27 results, Mr. Vikram Vuppala – Chairman & MD said,
"Dialysis market across the World continues to grow due to the increasing burden of Diabetes and Hypertension as well as improving access due to various interventions. NephroPlus continues to grow healthily in India and international markets and expect margins to remain in healthy range.

We are excited to open NephroPlus in Kazakhstan, which will be our 6th market. The two clinics we acquired are a good starting point for us to better understand the local market nuances before we start scaling this network in Kazakhstan.

We have technically qualified in the Saudi Arabia's Ministry of Health tender. We are one of the 12 Providers who qualified to bid for 4 regions in this tender and hence expect the process to be very competitive.

We continue to invest in Strategic initiatives to strengthen our Platform over the long term. One major initiative is that we recently launched a new NIDA initiative – NephroPlus International Dialysis Academy. We intend to train lot of nurses from Philippines and India to enable us to expand in International markets."

Mr Rohit Singh, Group Chief Executive Officer said,
"H1FY27 took NephroPlus into a sixth country, with our network now at 570 clinics across 6 countries. Revenue grew 23.6% year-on-year to ₹585.2 crore and Adjusted EBITDA rose 15.3% to ₹134.4 crore. We delivered over 21 lakh treatments, up 12.6% YoY, with guest volumes up 9.6%. Growth came from a combination of new market entries, acquisitions and steady volumes across our established networks.

Kazakhstan is our newest market, entered through the acquisition of 2 clinics with 34 machines in Almaty, giving us a base from which to assess the wider Central Asian opportunity. In the Philippines, 10 acquisitions during the half took our network there to 55 clinics. In Saudi Arabia, our Riyadh clinic is now operational and home dialysis has commenced in both Riyadh and Jeddah.

Clinically, we are piloting Peritoneal Dialysis in Punjab, with nearly 50 guests onboarded. We have also begun centre-level analysis of the barriers keeping guests on twice-weekly sessions and of earlier vascular access, both of which bear directly on guest survival.

On technology, automated off-hours calling now gathers guest feedback and speeds up query resolution, while in-house agents are compressing our development and quality assurance cycles so improvements reach guests sooner. Expansion is only as good as the care it carries."

Mr. Prashant Goenka, Chief Financial Officer added,
"Our India platform keeps delivering, and it continues to carry us across borders into new countries. International business is now 47% of our revenue. In H1 FY27, revenue grew 23.6% year-on-year, beating our 15–20% guidance, as we have every single quarter. Adjusted EBITDA grew 15.3%, and Adjusted PAT grew 34.7%.

We are investing with discipline. In H1 FY27, we spent ₹102 crore on capex, adding 40 clinics in India and 11 in the Philippines, and we opened in two new countries, Saudi Arabia and Kazakhstan. That gives us more ways to grow. We converted 69% of our EBITDA into cash, and with more than ₹500 crore in liquidity, we have the resources to fund our plans and the confidence to meet our guidance.

As we enter new markets, margins and returns will move during the ramp-up. That's the nature of building something new. But they will stay healthy, because our goal is clear: a scalable global dialysis platform built for the long term."

About Nephrocare Health Services Limited:

Nephrocare Health Services Limited (NSE: NEPHROPLUS; BSE: 544647) is Asia's largest dialysis network, owning and operating 570 dialysis centres under the NephroPlus brand. The Company has a strong and growing footprint across India, Nepal, the Philippines, Uzbekistan, Saudi Arabia and Kazakhstan, delivering standardized, high-quality dialysis through a scalable and asset-light model.

For more information, contact:

Company: Nephrocare Health Services Limited

Mr. Rohit Aidasani

E-mail: investor.relations@nephroplus.com

Investor Relations: Strategic Growth Advisors

Mr. Sagar Shroff / Mr. Ayush Haria

Contact: +91 98205 19303 / +91 98204 62966

E-mail: sagar.shroff@sgapl.net / ayush.haria@sgapl.net

Safe Harbour statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.